Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Neurofibroma, Plexiform 1Metastatic Solid Tumors. 1Melanoma 1Lymphoma 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Acute 1Hematologic Diseases 1Gastrointestinal Stromal Tumors 1Dermoid Cyst 1Burkitt Lymphoma 1Blast Crisis 1

Interventions

Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Metastatic Solid Tumors. × Imatinib Mesylate × Clear all
NCT00159016 2011-04-28

Role of Glivec in Patients With Tumor Cells Positive for C-kit or PDGFR; a Multi Center Study.

Hadassah Medical Organization

Phase 2 Withdrawn
100 enrolled
Other solid neoplasm

Metastatic Solid Tumors.

Data powered by HemOnc (CC BY 4.0) Colophon âš¡